Send to

Choose Destination
Mol Cancer Ther. 2019 Feb;18(2):301-311. doi: 10.1158/1535-7163.MCT-18-0464. Epub 2018 Nov 7.

Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.

Author information

Department of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky.
Adichunchanagiri Institute for Molecular Medicine, AIMS, Karnataka, India.
Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee.
Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, Karnataka, India.
Department of Public Health, University of Miami Miller School of Medicine, Miami, Florida.
Department of Pathology, University of Colorado, Denver, Colorado.
Department of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida.
Contributed equally


Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation present in an overwhelming majority of PDAC cases, have been largely ineffective. However, inhibition of downstream components in the KRAS signaling cascade provides promising therapeutic targets in the management of PDAC and warrants further exploration. Here, we investigated Urolithin A (Uro A), a novel natural compound derived from pomegranates, which targets numerous kinases downstream of KRAS, in particular the PI3K/AKT/mTOR signaling pathways. We showed that treatment of PDAC cells with Uro A blocked the phosphorylation of AKT and p70S6K in vitro, successfully inhibited the growth of tumor xenografts, and increased overall survival of Ptf1aCre/+;LSL-KrasG12D/+;Tgfbr2flox/flox (PKT) mice compared with vehicle or gemcitabine therapy alone. Histologic evaluation of these Uro A-treated tumor samples confirmed mechanistic actions of Uro A via decreased phosphorylation of AKT and p70S6K, reduced proliferation, and increased cellular apoptosis in both xenograft and PKT mouse models. In addition, Uro A treatment reprogrammed the tumor microenvironment, as evidenced by reduced levels of infiltrating immunosuppressive cell populations such as myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T cells. Overall, this work provides convincing preclinical evidence for the utility of Uro A as a therapeutic agent in PDAC through suppression of the PI3K/AKT/mTOR pathway.

[Available on 2020-02-01]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center